Via a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body
Fighting cancer means killing cancer cells. However, oncologists know that it’s also important to halt the movement of cancer cells before they spread throughout the body. New research, published today in the journal Nature Communications, shows that it may be possible to freeze cancer cells and kill them where they stand.
Raymond Bergan, M.D., Division Chief of Hematology and Medical Oncology and professor of medicine at OHSU, says that the majority of cancer treatment therapies today are directed toward killing cancer. To date, he says, no one has developed a therapy that can stop cancer cells from moving around the body.
“For the vast majority of cancer—breast, prostate, lung, colon, and others—if it is detected early when it is a little lump in that organ and it has not spread, you will live. And generally, if you find it late, after it has spread throughout your body, you will die,” says Bergan, also the associate director of medical oncology in the OHSU Knight Cancer Institute and director of the OHSU Bergan Basic Research Laboratory. “Movement is key: the difference is black and white, night and day. If cancer cells spread throughout your body, they will take your life. We can treat it, but it will take your life.”
For that reason, the study of cancer cell movement, or motility, has been the focus of his group’s research for several decades.
Stopping cancer cell movement
In 2011, Bergan and team took a novel approach to their research by working with chemists to jointly discover a drug that will inhibit the movement of cancer cells.
The Nature Communications paper outlines the multidisciplinary team’s work with KBU2046, a compound that was found to inhibit cell motility in four different human cell models of solid cancer types: breast, prostate, colon and lung cancers.
“We used chemistry to probe biology to give us a perfect drug that would only inhibit the movement of cancer cells and wouldn’t do anything else,” Bergan says. “That basic change in logic lead us to do everything we did.”
A multidisciplinary team
The team of investigators includes Bergan’s team at OHSU, a chemist from Northwestern University as well as researchers from Xiamen University in China, the University of Chicago, and the University of Washington.
Ryan Gordon, Ph.D., research assistant professor in the OHSU School of Medicine and co-director of the Bergan lab, says drawing upon the strengths of this cross-functional group was key to the research’s success.
“As we identified areas we were lacking, we looked at new cutting-edge technologies, and if there was something that didn’t meet our needs, we developed new assays to address our needs,” he says.
The lab of Karl Scheidt, Ph.D., professor of chemistry and professor of pharmacology; director of the Center for Molecular Innovation and Drug Discovery; and executive director of the NewCures accelerator at Northwestern University, was responsible for the design and creation of new molecules which were then evaluated by Bergan’s team for their ability to inhibit cell motility. Using chemical synthesis approaches, Scheidt and team accessed new compounds that minimized motility in tumor cells, with few side effects and very low toxicity.
“We’ve taken a clue provided by nature and through the power of chemistry created an entirely new way to potentially control the spread of cancer,” Scheidt says. “It’s been a truly rewarding experience working together as a team toward ultimately helping cancer patients.”
Refining the drug
Bergan notes the process for narrowing down the specific drug compound was a process of refinement.
“We started off with a chemical that stopped cells from moving, then we increasingly refined that chemical until it did a perfect job of stopping the cells with no side effects,” he says. “All drugs have side effects, so you look for the drug that is the most specific as possible. This drug does that.”
Bergan says the key to this drug was engaging the heat shock proteins—the “cleaners” of a cell. “The way the drug works is that it binds to these cleaner proteins to stop cell movement, but it has no other effect on those proteins.”
He says it is a very unusual, unique mechanism that “took us years to figure out.”
“Initially, nobody would fund us,” Bergan says. “We were looking into a completely different way of treating cancer.”
Next step: testing the drug in humans
Ultimately, Gordon says the goal of this research is to look for a new therapeutic to benefit humans.
“The eventual promise of this research is that we’re working toward developing a therapeutic that can help manage early stage disease, preventing patients from getting the more incurable later-stage disease,” he says.
He’s quick to note this work has not been tested in humans, and doing so will require both time and money. The team’s best estimate is that will take about two years and five million dollars of funding. They are currently raising money to do IND (investigational new drug) enabling studies, a requirement to conduct a clinical trial of an unapproved drug or an approved product for a new indication or in a new patient population.
In addition, Drs. Bergan and Scheidt have founded a company, Third Coast Therapeutics, aimed to bring this type of therapy to patients.
“Our eventual goal is to be able to say to a woman with breast cancer: here, take this pill and your cancer won’t spread throughout your body. The same thing for patients with prostate, lung, and colon cancer,” Bergan says. “This drug is highly effective against four cancer types (breast, colon, lung, prostate) in the in vitro model so far. Our goal is to move this forward as a therapy to test in humans.”
Bergan says his team feels lucky to have the opportunity to conduct this challenging research at the OHSU Knight Cancer Institute, an institute dedicated to novel approaches to detecting and treating cancer.
“What early detection is trying to do is detect an early, lethal lesion. Cancers are lethal because they move,” he says. “This drug is designed to stop that movement.”
Learn more: Research team discovers drug compound that stops cancer cells from spreading
The Latest on: Stopping cancer cells from spreading
[google_news title=”” keyword=”stopping cancer cells from spreading” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Stopping cancer cells from spreading
- FDA approves Imdelltra for patients with extensive-stage small cell lung canceron May 17, 2024 at 10:18 am
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer.
- GLIA Integrated Healthcare Offers a Gentler, Non-Invasive Approach to Cancer Careon May 17, 2024 at 9:19 am
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries Boomi and RSM US LLP Extend Strategic Business Alliance to Empower Middle ...
- Kate Middleton's Battle with Cervical Cancer: An Update on Her Health and the Importance of HPV Awarenesson May 16, 2024 at 8:27 am
More precisely, cervical cancer, which is a proliferation of cells that begins in the cervix ... followed by preventive chemotherapy to stop the spread of cancer. According to the most recent updates, ...
- Hypnotherapy helps woman beat cancer as she says 'I could feel chemo killing it'on May 14, 2024 at 8:57 am
Faye Roberts, 46, was diagnosed with stage three breast cancer after finding a lump under her right breast while in the shower in March 2023 - she underwent five months of chemotherapy ...
- Woman fights triple-negative breast canceron May 13, 2024 at 8:08 am
Holly Hernandez of Center, formerly of Verdigre, is fighting more than triple-negative breast cancer; she is also on a mission to spread awareness regarding the diagnosis and what it means ...
- Mayo Clinic Q&A: Tonsil cancer: What is it and how do you prevent it?on May 12, 2024 at 7:14 am
The HPV vaccine has been available since 2006 in the U.S. It's FDA-approved for males and females ages 9 to 45. For cancer prevention, we know from studies that earlier is better, before sexual ...
- Cancer Cells Spread When They Stop Recycling Wasteon May 7, 2024 at 5:00 pm
In their absence, tumor cells spread to the lung, an organ to which this cancer type doesn’t typically venture. The gene that codes for p47 protein produced the biggest difference when depleted, ...
- How Does The Drug Abemaciclib Treat Breast Cancer?on May 7, 2024 at 8:27 am
The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat ...
- Stopping blood canceron May 7, 2024 at 12:46 am
However, in myeloproliferative neoplasia (MPN), a group of malignant bone marrow diseases, the process gets out of control due to mutations in the stem cells and blood cancer develops. MPNs mainly ...
via Bing News